Literature DB >> 901706

Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.

J Meier, E Nüesch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 901706      PMCID： PMC1429071          DOI： 10.1111/j.1365-2125.1977.tb00726.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.

Authors:  C Bahr; G Alván; M Lind; B Mellström; V Sjöqvist
Journal:  Acta Pharm Suec       Date:  1974-12

3.  Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol.

Authors:  C G Regårdh
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

4.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia.

Authors:  E E Ohnhaus; E Nüesch; J Meier; F Kalberer
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

7.  Influence of first-pass effect on availability of drugs on oral administration.

Authors:  M Gibaldi; R N Boyes; S Feldman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

Review 8.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335
View more
  10 in total

1.  Cardiac dose-response relationships of oral and intravenous pindolol.

Authors:  S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

2.  Effects of age and smoking on the pharmacokinetics of pindolol and propranolol.

Authors:  G Hitzenberger; P Fitscha; T Beveridge; E Nüesch; W Pacha
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 4.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

5.  Metabolism of pindolol in patients with renal failure.

Authors:  E E Ohnhaus; H Heidemann; J Meier; G Maurer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Study of the bioavailability of pindolol in malabsorption syndromes.

Authors:  D Evard; J P Aubry; Y Le Quintrec; G Cheymol; A Cheymol
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

7.  A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.

Authors:  W H Aellig; H H Narjes; E Nüesch; R J Oertle; J E Devos; W Pacha
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Elimination of pindolol in liver disease.

Authors:  E E Ohnhaus; U Münch; J Meier
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.

Authors:  Andrew A Udy; Paul Jarrett; Janine Stuart; Melissa Lassig-Smith; Therese Starr; Rachel Dunlop; Steven C Wallis; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care       Date:  2014-11-29       Impact factor: 9.097

10.  Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review.

Authors:  Wallace Bok-Thoe Hong; Wee Kiat Tan; Lawrence Siu-Chun Law; David Eng-Hui Ong; Elaine Ah-Gi Lo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-01       Impact factor: 2.441
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.